Risk factors for choroidal neovascularization in young patients: a case-control study
- PMID: 8886585
- DOI: 10.1007/BF01204172
Risk factors for choroidal neovascularization in young patients: a case-control study
Abstract
A pair-matched, case-control design was used to study exposure to Histoplasma capsulatum and other environmental factors, and to determine various host characteristics including human leukocyte antigen (HLA) typings in 94 young patients with macular choroidal neovascularization (CNV) and in 94 controls with other eye diseases. Patients with two types of retinal patterns were studied: Type I, or those with CNV with one or no chorioretinal atrophic spots in the posterior pole or periphery (n = 51), and Type II, or those with CNV and 2 or more chorioretinal atrophic spots (n = 43). Our purpose was to explore whether these two variants of idiopathic CNV have different and distinguishable epidemiologies which may or may not be related to prior exposure to Histoplasma. We found that histoplasmin skin tests were negative in all but two Type I cases. The combination of the HLA-B7 and HLA-DR2 markers (but not either marker alone) was significantly increased in Type I cases. Among Type II cases, HLA-B7, HLA-DR2, HLA-DQ1, a positive histoplasmin skin test, myopic refractive error, prior residence in a histoplasmosis endemic area, occupations involving exposure to animals, and hypertension were all significantly increased. Histoplasmin skin test responses were positive in 18 Type II cases (45%). In the multivariate analysis, only DR2 and the combined presence of DQ1 and a positive histoplasmin skin test remained predictive of Type II disease. Our findings suggest that histoplasmin sensitivity is associated with some, but not all, cases of Type II disease. However, histoplasmin sensitivity appears to have no relationship to Type I disease. HLA factors may play a role in both disease types, possibly by producing a modified immune response to Histoplasma and/or other unidentified agents.
Similar articles
-
Five-year follow-up of fellow eyes of individuals with ocular histoplasmosis and unilateral extrafoveal or juxtafoveal choroidal neovascularization. Macular Photocoagulation Study Group.Arch Ophthalmol. 1996 Jun;114(6):677-88. doi: 10.1001/archopht.1996.01100130669006. Arch Ophthalmol. 1996. PMID: 8639078 Clinical Trial.
-
Scanning laser ophthalmoscope fundus perimetry after surgery for choroidal neovascularization.Am J Ophthalmol. 1998 May;125(5):657-65. doi: 10.1016/s0002-9394(98)00014-2. Am J Ophthalmol. 1998. PMID: 9625549
-
Immunologic, genetic and social human risk factors associated to histoplasmosis: studies in the State of Guerrero, Mexico.Mycopathologia. 1997;138(3):137-42. doi: 10.1023/a:1006847630347. Mycopathologia. 1997. PMID: 9468664
-
[A new approach for studying the retinal and choroidal circulation].Nippon Ganka Gakkai Zasshi. 2004 Dec;108(12):836-61; discussion 862. Nippon Ganka Gakkai Zasshi. 2004. PMID: 15656089 Review. Japanese.
-
Current management of choroidal neovascularization.Ann Ophthalmol. 1988 Nov;20(11):415-20, 423. Ann Ophthalmol. 1988. PMID: 2466432 Review.
Cited by
-
EFFICACY AND SAFETY OF RANIBIZUMAB FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION DUE TO UNCOMMON CAUSE: Twelve-Month Results of the MINERVA Study.Retina. 2018 Aug;38(8):1464-1477. doi: 10.1097/IAE.0000000000001744. Retina. 2018. PMID: 28704254 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials